Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05822245
PHASE1/PHASE2

A Study of PER-001 in Participants With Open-Angle Glaucoma

Sponsor: Perfuse Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.

Official title: A Phase 1/2a Study to Evaluate Safety, Tolerability, and Pharmacodynamic Effect After Single Administration of PER-001 Intravitreal Implant in Participants With Open-Angle Glaucoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2023-05-25

Completion Date

2026-04-04

Last Updated

2025-04-15

Healthy Volunteers

No

Interventions

DRUG

PER-001 Intravitreal Implant - Low Dose

PER-001 Low Dose Intravitreal Implant

DRUG

PER-001 Intravitreal Implant - High Dose

PER-001 High Dose Intravitreal Implant

DRUG

PER-001 Intravitreal Implant - Sham

PER-001 Intravitreal Sham

Locations (1)

Perfuse Therapeutics, Inc.

San Francisco, California, United States